Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports

Vineet Tyagi1, Jason Theobald2, James Barger1, Mark Bustoros2, N. Sumru Bayin2,5, Aram S. Modrek2, Michael Kader2, Erich G. Anderer7, Bernadine Donahue3,8, Girish Fatterpekar4, Dimitris G. Placantonakis2,5,6

1Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT; 2Departments of Neurosurgery, Radiation Oncology, Radiology, 3Kimmel Center for Stem Cell Biology, 4Brain Tumor Center, NYU School of Medicine, 5Division of Neurosurgery, Maimonides Medical Center, Brooklyn; 6Maimonides Cancer Center, Brooklyn, New York, USA

E-mail: Vineet Tyagi - vineet.tyagi@nymc.org; Jason Theobald - jason.theobald@nymc.org; James Barger - james.barger@nymc.org; Mark Bustoros - markbustoros@yahoo.com; N. Sumru Bayin - nermin.bayin@nymc.org; Aram S. Modrek - aram.modrek@nymc.org; Michael Kader - michael.kader@nymc.org; Erich G. Anderer - erich.anderer@nymc.org; Bernadine Donahue - bernadine.donahue@nymc.org; Girish Fatterpekar - girish.fatterpekar@nymc.org; Dimitris G. Placantonakis - dimitris.placantonakis@nymc.org

*Corresponding author
#These authors are equally contributors to this work

Received: 05 January 16 Accepted: 28 May 16 Published: 26 August 16

Abstract

Background: Previous reports have proposed an association between traumatic brain injury (TBI) and subsequent glioblastoma (GBM) formation.

Methods: We used literature searches and radiographic evidence from two patients to assess the possibility of a link between TBI and GBM.

Results: Epidemiological studies are equivocal on a possible link between brain trauma and increased risk of malignant glioma formation. We present two case reports of patients with GBM arising at the site of prior brain injury.

Conclusion: The hypothesis that TBI may predispose to gliomagenesis is disputed by several large-scale epidemiological studies, but supported by some. Radiographic evidence from two cases presented here suggest that GBM formed at the site of brain injury. We propose a putative pathogenesis model that connects post-traumatic inflammation, stem and progenitor cell transformation, and gliomagenesis.

Key Words: Brain tumor, glioblastoma, traumatic brain injury

INTRODUCTION

Glioblastoma (GBM) is the most common and deadly brain malignancy, with over 10000 new cases in the US annually and a median survival of only 14–16 months after surgical resection and concurrent chemoradiotherapy. Molecular analysis of GBM biospecimens has led to the identification of specific driver mutations, which have formed the basis for subtyping GBM into the following groups: Proneural, neural, classical, and mesenchymal. In a minority of cases, glioma or GBM arises in the context of specific genetic conditions caused by germline mutations in tumor suppressor genes, namely, neurofibromatosis 1 (NF1), tuberous sclerosis (TSC), and Li-Fraumeni syndrome (TP53). A rare genetic condition called Ollier disease, This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Tyagi V, Theobald J, Barger J, Bustoros M, Bayin NS, Modrek AS et al. Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports. Surg Neurol Int 2016;7:78. http://surgicalneurologyint.com/Traumatic-brain-injury-and-subsequent-glioblastoma-development:-Review-of-the-literature-and-case-reports/
which is caused by mosaicism for a gain-of-function mutation in the gene encoding isocitrate dehydrogenase (IDH1), increases the risk for glioma formation, along with enchondromas.\textsuperscript{[2,40]} Family history has also been linked to increased risk for GBM. Recent genome-wide association studies (GWAS), have pointed out single nucleotide polymorphisms (SNPs) that confer increased predisposition to developing glioma.\textsuperscript{[43,46,47,51,53,55]} A notable such SNP is located on chromosome 8q24.21, within the locus of a long non-coding RNA (lncRNA) named CCDC26, which increases glioma risk approximately five times.\textsuperscript{[43,46,47]} However, the role of predisposing genetic and environmental factors in gliomagenesis is still not well defined.

Environmental risk factors for GBM remain poorly defined, with the exception of exposure to ionizing radiation.\textsuperscript{[39]} Here, we discuss a less known putative risk factor for gliomagenesis, traumatic brain injury (TBI).\textsuperscript{[3,14,56]} In rare instances, formation of GBM has been documented in brain areas that were previously affected by injury. In the limited literature describing the association between TBI and GBM, the following criteria have been established which are suggestive of a causal relationship (reviewed in\textsuperscript{[16]}):

1. The injury must be severe enough to cause a tissue repair process to commence;
2. The area of the traumatic injury should correspond directly with the location of the subsequent GBM;
3. There should be a gap of at least 1 year between the injury to the brain and the appearance of the tumor. A longer latent period is considered to be a stronger evidence of a causal relationship.

Here, we present two patients who developed GBM at the exact same site where they had suffered TBI several years ago. We also review relevant epidemiological studies, which are overall equivocal on the association between TBI and GBM. Finally, we propose a mechanism that could explain the biological link between TBI and gliomagenesis by invoking inflammation as the trigger for oncogenic transformation of neural stem and progenitor cells that migrate to the injured tissue for repair. Chronic inflammation has been shown to be a major predisposing factor for many solid tumors, including, but not limited to, hepatocellular carcinoma and colon cancer.\textsuperscript{[12]} However, such a link has not been explored in gliomagenesis because of distinct immune properties of the brain. We postulate that, in a subset of patients, post-traumatic inflammation in the brain may predispose neural cells toward oncogenic transformation and glioma initiation.

**MATERIALS AND METHODS**

We performed literature searches on PubMed to identify epidemiological studies that investigated the link between brain injury and GBM formation. We also collected and analyzed clinical and radiographic data from two patients with a history of TBI, who subsequently developed GBM.
the overall study. This increased odds ratio may indicate that the severity of the injury may correlate to the risk of developing a tumor. We hypothesize that this correlation may be due to the fact that more severe injuries may induce more inflammation.

A study done by Preston-Martin et al. found that head injury resulting in loss of consciousness or a permanent scar had an odds ratio of 1.9, which may lend some credence to the connection between brain injury severity and subsequent tumor development. Monteiro et al. found that patients with TBI had increased propensity for developing brain tumors (OR = 1.49). This study also found that having two or more brain injuries resulted in an even higher odds ratio (3.14; adjusted for age, gender, and schooling), supporting the connection between severity and frequency of injury and subsequent tumor formation.

CASE REPORTS

Patient 1
This patient is a 65-year-old left-handed man, who suffered serious head trauma causing a large left frontal contusion at age 54 after a fall at the workplace. At that time, he was placed in a medically induced coma for 3 days. Serial imaging after the injury demonstrated encephalomalacia and gliosis at the site of the contusion [Figure 1]. He developed seizures 7 months after the injury. His seizures were well-controlled on lamotrigine until 11 years later when their frequency and severity increased. Imaging at that time remained unchanged. Three months later, he developed status epilepticus. Magnetic resonance imaging (MRI) of the brain revealed a large 4 cm heterogeneously enhancing tumor with a necrotic center in the left frontal lobe [Figure 1]. The tumor was in the same location as the original injury. Of note, it had been a mere 3 months since his last serial MRI, which showed no evidence of tumor.

In preparation for resection of the tumor, a Wada Test revealed bilateral hemispheric language dominance. To avoid damaging language-processing centers, awake language mapping was attempted during planned operative resection. The patient became agitated during language mapping and the surgeon opted to place subdural grid electrodes for extraoperative speech mapping, which revealed no regions associated with language function in the vicinity of the tumor. In a second operative procedure under general anesthesia, he underwent uneventful resection of >90% of the tumor with residual in the left insula. Histopathologic analysis confirmed the diagnosis of GBM. The Ki-67 immunolabeling index using MIB1 antibody was up to 25%. Immunohistochemistry for the R132H mutation in IDH1 was negative.

After surgery, he was treated with concurrent chemoradiotherapy (Stupp protocol). However, the tumor recurred rapidly and he expired within 4 months after surgery.

Patient 2
This patient is a 54-year-old right-handed man who suffered a large contusion and severe injury to the inferior right frontal lobe in an automobile accident at age 47 [Figure 2]. Shortly after the injury, he developed post-traumatic hydrocephalus that was treated with a right frontal ventriculoperitoneal shunt. Subsequently, he required placement of a cardiac pacemaker that precluded imaging with MRI. He was followed with serial computed tomography (CT), which showed resolution of the contusion and development of encephalomalacia at the site of the inferior right frontal injury.

Seven years after the injury, he came again to medical attention due to headaches and confusion. CT imaging indicated a 4 cm heterogeneously enhancing inferior right frontal mass at the site of the brain injury. There was extensive vasogenic edema surrounding the lesion. He underwent right frontal craniotomy for gross total resection of the mass, which was diagnosed as GBM. Immunohistochemistry for the R132H mutation in IDH1 was negative. He was subsequently treated with chemoradiotherapy as per Stupp protocol. As per the most recent follow-up 8 months post-resection, he remains neurologically intact with no evidence for recurrence on CT.
DISCUSSION

Epidemiological studies are largely equivocal on the link between TBI and subsequent formation of malignant glioma. In fact, large-scale studies have shown no correlation. However, the two presented cases show GBM formation at the site of prior brain injury. Our hypothesis is that, in some patients, an underlying biological vulnerability predisposes them to gliomagenesis after brain trauma. What are the mechanisms that could potentially explain injury-driven gliomagenesis?

We propose that the inflammatory response that ensues after TBI is linked to oncogenic transformation of neural stem and progenitor cells that chemotactically migrate to the injured site in response to inflammation. In the acute post-trauma period, there is sequential mobilization of resident brain microglia and myeloid inflammatory cells to the site of injury. Peripheral neutrophils, monocytes, and eosinophils are recruited to the site within hours and can remain for extended periods of time. These inflammatory cells can contribute to oncogenesis via the generation of reactive oxygen species (ROS), which have mutagenic properties, or via secretion of growth factors and cytokines that have mitogenic effects on neural stem and progenitors cells, in addition to prolonging the inflammatory response. For example, eosinophils have been linked to the initiation and progression of GBM. Eosinophilic granular contents have been shown to cause significant damage to tissues in an effect known as the Gordon phenomenon. Eosinophilic derived neurotoxin (EDN), eosinophil cationic protein, and eosinophil protein X (EPX) have been experimentally shown to produce cellular damage. In addition, eosinophil peroxidases generate ROS, which may lead to mutagenesis. A number of inflammatory cytokines, including IL-1, TNF, IL-10, IL-6, IL-8, and MCP-1, are known to be upregulated in the context of TBI and facilitate recruitment of myeloid immune cells. Furthermore, studies have provided evidence that single nucleotide polymorphisms (SNPs) in interleukin-4 receptor alpha (IL-4Rα) and interleukin-13 (IL-13) may be risk factors in GBM formation. Cytokines IL-4 and IL-13 both activate the IL-4Rα receptor on cells of the immune system, leading to similar downstream responses, which ultimately result in the release of chemoattractants, such as eotaxin and MCP-1. These chemokines result in the migration of eosinophils and monocytes into the area of damage. Stem cell migration to injury site

Neural stem cells in the adult brain localize primarily to two neurogenic areas, namely, the subventricular
zone of the hippocampal dentate gyrus (for review see[33]). There is also speculation that neural stem or progenitor cells may reside in cortical areas, however, this is debatable.[4] Neural stem cells in neurogenic niches generate lineages that populate the brain: Neurons, astrocytes, and oligodendrocytes. Neural stem cells and descendant progenitor cells chemotactically migrate to the sites of brain injury and participate in the repair and recovery.[15,19,24,48,54] Ependymal cells, which line the inner walls of the ventricles, may also proliferate and differentiate into neuroblasts and astrocytes following trauma in mice and humans.[49] Such chemotraction-mediated migration has been demonstrated in the case of various injury-generating insults, namely, ischemia, demyelination, and, importantly for our purposes, physical trauma.[31] GBM may, therefore, result from transformation of neural stem or progenitor cells as they migrate to the injury to repair tissue damage.

The oncogenic potential of neural stem cells has been suggested by the observation that neurogenic niches in the brain are sensitive to chemical oncogenesis.[32,41,50] Experimental models involving overexpression of oncogenes and inactivation of tumor suppressor genes in neural stem cells suggest that they can generate GBM tumors (reviewed in [33]). The fact that GBM tumors are frequently found in the periventricular zone or in direct contact with the subventricular zone supports this hypothesis.[1,5,10,26] Genetic models in mice have raised the possibility that oligodendrocyte progenitors may also represent a putative cell-of-origin in GBM.[50] Other studies have suggested that even terminally differentiated brain cells, such as neurons and astrocytes, can give rise to GBM by undergoing dedifferentiation driven by genetic alterations.[17,31] In addition, astrocytes near a stab wound proliferate within their lineage in vivo, however, a fraction of astrocytes from injured brain tissue demonstrates long-term stem cell-like activity in an in vitro neurosphere assay, suggesting the possibility of a return to multipotency under certain conditions.[7,28] Collectively, these observations suggest that several neural cell types that migrate to TBI sites are capable of undergoing oncogenic transformation.

**CONCLUSION**

In conclusion, large-scale epidemiological studies have not shown a definitive link between TBI and increased risk of developing GBM. However, the two patients presented here developed GBM at the site of their brain injury several years later. It is, therefore, possible that an underlying biological vulnerability in a subset of patients with TBI may predispose them to gliomagenesis. We propose a putative model that links neuroinflammation to mutagenesis in neural stem and progenitor cells migrating to the site of injury, leading to their neoplastic transformation and glioma initiation. In the future, as molecular mechanisms of gliomagenesis and the brain’s response to TBI become clearer, we hope to identify the biological mechanisms that make a subset of patients susceptible to brain tumor formation after injury.

**Financial support and sponsorship**

N. Sunru Bayin received support from NYSTEM Institutional training grant #CO26880. Dimitris G. Placantonakis received support from NIH/NINDS IR21NS087241-01, NIH/NINDS IR21NS087775-01, NIH/NINDS 1R03NS087349-01, NIH/NCI 2P30CA16087-33, NIH/NCATS UL1 TR000038, NYU Cancer Institute, NYU Clinical and Translational Science Institute and the B*Cure Foundation.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Adeberg S, Kö nig L, Bostel T, Harrabi S, Welzel T, Debus J, et al. Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. Int J Radiat Oncol Biol Phys 2014;90:886-93.
2. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of ID1H and IDH2. Nature Genet 2011;43:1262-5.
3. Anselmi E, Vallisa D, Berté R, Vanzo C, Cavanna L. Post-traumatic glioma: Report of two cases. Tumori 2006;92:175-7.
4. Barnabé-Heider F, Göritz C, Sabelström H, Takebayashi H, Pflieger PW, Meletis K, et al. Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell 2010;7:470-82.
5. Bohman LE, Swanson KR, Moore JL, Rockne R, Mandigo C, Hankinson T, et al. Magnetic resonance imaging characteristics of glioblastoma multiforme: Implications for understanding glioma ontogeny. Neurosurgery 2010;67:1319-27.
6. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
7. Buffo A, Rite I, Tripathi P, Lepier A, Colak D, Horn AP, et al. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc Natl Acad Sci U S A 2008;105:3581-6.
8. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
9. Carlén M, Meletis K, Göritz C, Darsalia V, Evgeniev E, Tanigaki K, et al. Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci 2009;12:259-67.
10. Chaichana KL, McGirt MJ, Frazier J, Attanello F, Guerrero-Cazares H, Quinones-Hinojosa A. Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J Neurooncol 2008;89:219-24.
11. Chen YH, Keller JJ, Kang JH, Lin HC. Association between traumatic brain injury and the subsequent risk of brain cancer. J Neurotrauma 2012;29:1328-33.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
13. Curran CS, Bertics PJ. Eosinophil in glioblastoma biology. J Neuroinflammation 2012;9:11.
14. Di Trapani G, Carnevale A, Scerrati M, Colosimo C, Vaccario ML, Mei D. Post-traumatic malignant glioma. Report of a case. Ital J Neurosurg 1996;17:283-6.
15. Elvira G, García I, Gallo J, Benito M, Montesinos P, Holgado-Martin E, et al. Detection of mouse endogenous type B astrocytes migrating towards brain lesions. Stem Cell Res 2015;14:114-29.
et al et al et al et al et al et al.

35. Mossman BT. Introduction to serial reviews on the role of reactive oxygen and nitrogen species (ROS/RNS) in lung injury and diseases. Free Radic Biol Med 2003;34:1115-6.

34. Monteiro GT, Pereira RA, Koifman RJ, Koifman S. Head injury as a risk factor for brain tumors in children: Results from a multicenter case-control study. Epidemiology 1996;7:485-9.

33. Modrek AS, Bayin NS, Placantonakis DG. Brain stem cells as the cell of origin of gliomas in mice. Science 2012;338:1080-4.

32. Mc DA, Opeskin K. Timing of early changes in brain trauma. Am J Forensic Med Pathol 2006;42:6549-65.

31. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.

30. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009;15:157-73.

29. Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998;9:109-16.

28. Lang B, Liu HL, Liu R, Feng GD, Jiao XY, Ju G. Astrocytes in injured adult rat spinal cord may acquire the potential of neural stem cells. Neuroscience 2004;128:775-83.

27. Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS One 2013;8:e68963.

26. Koos WT, Horacek A. Statistics of intracranial midline tumors in children. Acta Neurochir Suppl 1985;35:1-5.

25. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Genetic risk profiles identify different molecular etiologies for glioblastoma. Cell 2006;9:157-73.

24. Koos WT, Horaczek A. Subependymal zone cells in adult mice change after cerebral cortex injury. Brain Res 2004;996:213-26.

23. Hopewell JW. The subependymal plate and the genesis of gliomas. J Pathol 1975;117:101-3.

22. Inskip PD, Mellekjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998;9:109-16.

21. Halliday J, Holland EC. Connective tissue growth factor and the parallels between brain injury and brain tumors. J Natl Cancer Inst 2011;103:1141-3.

20. Hoopwell JW. The subependymal plate and the genesis of gliomas. J Pathol 1975;117:101-3.

19. Goings GE, Sahni V, Szele FG. Migration patterns of subventricular zone-derived neuroblasts and differentiated neuronal progeny within the subventricular zone following cerebral cortex injury. Mol Cell Neurosci 2003;24:171-89.

18. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.

17. Friedmann-Morvinski D, Busshong EA, Ke E, Suda Y, Marumoto T, Singer O, et al. Derivation of neurons and astrocytes by oncocogenes can induce gliomas in mice. Science 2012;338:1080-4.

16. Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophilic cationic protein and eosinophil protein X. J Allergy Clin Immunol 1982;70:361-6.

15. Friedmann-Morvinski D, Busshong EA, Ke E, Suda Y, Marumoto T, Singer O, et al. Derivation of neurons and astrocytes by oncocogenes can induce gliomas in mice. Science 2012;338:1080-4.

14. Monteiro GT, Preston-Martin S, McDaniel AM, Mueller BA, Holly EA. Head injury as a risk factor for brain tumors in children: Results from a multicenter case-control study. Epidemiology 1996;7:485-9.

13. Halliday J, Holland EC. Connective tissue growth factor and the parallels between brain injury and brain tumors. J Natl Cancer Inst 2011;103:1141-3.

12. Hopewell JW. The subependymal plate and the genesis of gliomas. J Pathol 1975;117:101-3.

11. Inskip PD, Mellekjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998;9:109-16.

10. Jin K, Sun Y, Xie L, Peel A, Mao XO, Batzeer S, et al. Directed migration of neuronal precursors into the ischemic cerebral cortex and stratum. Mol Cell Neurosci 2003;24:171-89.

9. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain 2013;136(Pt 1):28-42.

8. Koos WT, Horacek A. Statistics of intracranial midline tumors in children. Acta Neurochir Suppl 1985;35:1-5.

7. Kuperman DA, Schleimer RP. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 2008;8:384-92.

6. Lang B, Liu HL, Liu R, Feng GD, Jiao XY, Ju G. Astrocytes in injured adult rat spinal cord may acquire the potential of neural stem cells. Neuroscience 2004;128:775-83.

5. Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS One 2013;8:e68963.

4. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011;146:209-21.

3. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Suda Y, Gage FH, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009;15:110-6.

2. Mc DA, Opeskin K. Timing of early changes in brain trauma. Am J Forensic Pathol 1998;19:1-9.

1. Modrek AS, Bayin NS, Placantonakis DG. Brain stem cells as the cell of origin of glioma. World J Stem Cells 2014;6:43-52.

0. Monteiro GT, Pereira RA, Koifman RJ, Koifman S. Head injury and brain tumors in adults: A case-control study in Rio de Janeiro, Brazil. Eur J Cancer 2006;42:917-21.